期刊名称：CLINICAL PHARMACOLOGY & THERAPEUTICS
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
 Aims and scope of journal
Clinical Pharmacology & Therapeutics (CPT) is the authoritative cross-disciplinary journal in experimental and clinical medicine devoted to publishing advances in the nature, action, efficacy, and evaluation of therapeutics. CPT welcomes original articles, letters and communications in the emerging areas of translational, predictive and personalized medicine; new therapeutic modalities including gene and cell therapies; pharmacogenomics, proteomics and metabolomics; bioinformation and applied systems biology complementing areas of pharmacokinetics and pharmacodynamics, human investigation and clinical trials, pharmacovigilence, pharmacoepidemiology, pharmacometrics, and population pharmacology.
Commentaries and Point-Counterpoint provide a forum for perspectives in clinical pharmacology and therapeutics in the context of contemporary scientific, political, economic and social issues. State of the Art contributions summarize the latest advances in the science underpinning drug discovery, development, regulation and utilization. CPT highlights issues transforming the practice of clinical pharmacology, including ethics, education and public policy. Bench-to-bedside translation in therapeutics is presented in the context of clinical applications of basic pharmacology, discovery and translational medicine, and drug development.
Instructions to Authors
Submitting an article |
Benefits of publishing with CPT |
Top of page
Submitting an article
To find out how to prepare your manuscript, please click on Instructions for Authors. If you are ready to submit an article please click on Online Submission.
Complete instructions for preparing and submitting manuscripts online, including color artwork forms and Copyright forms, are provided at the online submission site. For online help and tutorials on how to use the online submission site, please click on Help.
Additional information and news can be found at Nautilus, the NPG blog for authors and aspiring authors. Top of page
Benefits of publishing with CPT
Clinical Pharmacology & Therapeutics (CPT) is the official journal of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), which is committed to publishing high quality, independently peer-reviewed research and review material.
The journal is published in partnership with Nature Publishing Group (NPG), which uses pioneering technologies, innovative formats and world-class production to provide premium information for scientific researchers in the public and private sectors, government agencies and educators.
A key strength of NPG is its close relationship with the scientific community. By working closely with scientists, listening to what they say, and always placing emphasis on quality rather than quantity, NPG is the leading scientific publisher at finding innovative solutions to scientists' information needs, both for the Nature-branded publications and those published on behalf of society partners, including the ASCPT.
Publishing with CPT and NPG provides an author with a wide range of benefits:
Copyright
The American Society for Clinical Pharmacology and Therapeutics requires authors to assign copyright of their published contributions upon acceptance of manuscripts. The form is available at the online submission site.
Online submission - reducing publication times
CPT uses an online submission system, which allows authors to submit papers via the Web. Speeding up the submission and refereeing process, this system also allows you to view the status of your paper online: http://mc.manuscriptcentral.com/cpt/
Quality
New original and review articles in CPT, as in all NPG journals, are published weekly online ahead of the archival print issue, ensuring the research is made publicly available and can be cited as soon as possible after acceptance for publication. The online publication is identical to the printed version and is not a preliminary, unedited version, thus maintaining the journal's tradition of excellence and the integrity of the published record.
Supplementary online material
Authors are invited to submit additional supporting material such as data sets or video for publication in the online version of the journal. Online supplementary material makes the most of the Web as a delivery platform and can often give articles greater depth, making them more useful to readers.
High standards
Authors who choose to publish in any NPG journal can be assured that its staff's publishing, editorial and production skills are committed to maintaining the highest possible quality and standards.
Exposure - widest possible readership
All NPG journals, including CPT, are available online via site licenses to academic, corporate and government institutions and consortia. Journals are available to members of these institutions at the click of a mouse, adding speed and visibility to authors' research papers.
Regular free e-mail alerts
Content published in CPT has the potential to reach scientists around the world who have signed up for NPG's free table of contents e-alerts, ensuring additional exposure to authors. These e-alerts allow recipients to click through to the full article if they subscribe or work at an institution with a site license, or click through to the article's abstract for other readers.
Focused subject areas on nature.com
From immunology to physics, genetics to materials, subject-specific areas provide a focused environment for readers, providing a monthly updated focus for a particular field.
Abstracting and indexing
CPT is included in the leading abstracting and indexing services including ISI, MEDLINE, EMBASE and BIOSIS. Extensive reference linking to MEDLINE, ISI and others via services such as Crossref and DOI numbers provide seamless online linking between articles and databases.
The Nature News Service provides information about exceptionally interesting papers published throughout NPG. More than 2,000 journalists and media organizations worldwide subscribe to the press service, ensuring that papers receive maximum exposure in the world's most important media channels including newspapers, magazines, radio and television.
Extending science further - global collaborations
NPG and the ASCPT support a number of global collaborations aimed at making current research available to a broader community of scientists and practitioners.
All NPG journals, including CPT, are in WHO's HINARI program, and in FAO's AGORA program, which provide free or low cost access to public institutions in developing countries.
Instructions to Authors
0009-9236z.pdf
Editorial Board
Editors
Editor-in-Chief
Scott Waldman, MD, PhD, FCP
Dr. Waldman is the Samuel MV Hamilton Endowed Professor of Medicine, the Chair of the Department of Pharmacology and Experimental Therapeutics, the Director of the Division of Clinical Pharmacology, and the Director of the Developmental Therapeutics program of the Kimmel Cancer Center at Thomas Jefferson University. He is a past president of ASCPT and served on its Board of Directors. Dr. Waldman holds an MD from Stanford University and a PhD from Thomas Jefferson University. He is a leading clinician investigator whose extensive research spans the pharmacology spectrum from molecular biology of signal transduction to novel diagnostics and therapeutics for cancer. His studies have resulted in more than 130 publications and have produced more than 45 awarded patents and patent applications worldwide.
Deputy Editor-in-Chief
Andre Terzic, MD, PhD
Dr. Terzic is a Professor of Medicine and Molecular Pharmacology and Experimental Therapeutics at the Mayo Clinic College of Medicine. He is a Mayo Foundation Endowed Career Scientist and program co-Director for the Postgraduate Cardiovascular Fellowship Program at the Mayo Graduate School of Medicine. Dr. Terzic received his MD from the School of Medicine at the University of Belgrade and continued his education at the University of Illinois, receiving a PhD in pharmacology. He is a past president of ASCPT and is active in many roles at the Mayo Clinic including Vice-Chairman of the Department of Cardiovascular Research and Director of the Cardiovascular Research Laboratory and the NIH Cardiovascular Training Program in Cardiovasology. Dr. Terzic is a widely published author and educator in the field of pharmacology.
Associate Editors
Arthur J. Atkinson, MD
Dr. Atkinson received his Bachelor of Arts degree in chemistry from Harvard College and his MD from Cornell University Medical College. After initiating the clinical pharmacology program at Northwestern University Medical School, Dr. Atkinson pursued such notable positions as Corporate Vice President for Clinical Development and Medical Affairs at the Upjohn Company and Adjunct Professor in the Center for Drug Development Science at Georgetown University. He was later appointed Senior Advisor in Clinical Pharmacology to the Director of the NIH Clinical Center. Dr. Atkinson is a Master of the American College of Physicians and has served as president for the American Board of Clinical Pharmacology and ASCPT. He has contributed to many professional societies as an editorial board member and is extensively published in the field of pharmacology.
Christine Haller, MD
Christine Haller, MD, Director of Global Safety at Amgen, is board certified in Clinical Pathology and Medical Toxicology. Widely published in scientific journals such as the New England Journal of Medicine and Clinical Pharmacology and Therapeutics, Dr. Haller's early research focused on the safety of dietary supplements used for weight loss and athletic performance while a faculty member in the Division of Clinical Pharmacology and Experimental Therapeutics at the UCSF School of Medicine. Her current work involves risk assessment and other safety aspects of early clinical drug development at Amgen. An active member of the American Society for Clinical Pharmacology and Therapeutics, Dr. Haller is the Vice Chair of the Therapeutic Drug and Toxicology Monitoring Scientific Section and served on the Scientific Program Committee from 2004 until 2006.
Raymond J. Hohl, MD, PhD
Dr. Hohl is the Holden Family Chair, Professor of Internal Medicine and Pharmacology, Associate Chair in the Department of Internal Medicine, Associate Director for Translational Research in the Holden Comprehensive Cancer Center. He received his Ph.D. in Pharmacology from Rush University. He is a Diplomate of the American Board of Internal Medicine, a Fellow at the American College of Physicians and has been recognized with such honors as the PMA Faculty Development Award in Clinical Pharmacology and the Laureate Award from the Iowa Chapter of the American College of Physicians. Dr. Hohl earned his MD at Rush Medical College. His clinical research interests focus on the evaluation of the potential role for pharmacologic inhibitors of this biosynthetic pathway in the treatment of various hematologic malignancies and solid tumors.
Peter K. Honig, MD, MPH
Dr. Honig is the Executive Vice President of Worldwide Regulatory Affairs and Product Safety for Merck Research Laboratories. After receiving his baccalaureate, medical and public health degrees from Columbia University, he joined the Food and Drug Administration as a medical review officer in the Division of Pulmonary and Allergy Drug Products. Dr. Honig is a Fellow of the American College of Physicians and a past president of ASCPT.
Laura P. James, MD
Dr. James is Section Chief, Clinical Pharmacology and Toxicology, Arkansas Children's Hospital and Professor in the Department of Pediatrics, University of Arkansas in Little Rock, AR. She received her Bachelor of Science degree from Furman University and her MD from the University of South Carolina. Her research is primarily focused on acetaminophen toxicity. Specifically, she is interested in biomarkers of acetaminophen toxicity (acetaminophen protein adducts) and the translation of knowledge on adducts generated from animal studies to the clinical arena, using new, sensitive assays. In addition, she studies pathways of recovery in the liver following acetaminophen toxicity in a mouse model and was recently awarded NIH funding to advance these studies. Dr. James is an active member of the Pediatrics Section of ASCPT and previously served on the Scientific Program Committee and as an abstract reviewer.
Richard L. Lalonde, PharmD
Dr. Lalonde is Vice President and Global Head of Clinical Pharmacology at Pfizer. He has been elected as a Fellow of the American College of Clinical Pharmacology, the American Association of Pharmaceutical Scientists and the American College of Clinical Pharmacy. He is the Chair of the Pharmacokinetics, Pharmacodynamics, and Pharmacometrics Section of ASCPT. Dr. Lalonde's research over the past 27 years has been focused on the application of pharmacokinetic and pharmacodynamic principles to the optimal utilization of drugs in patients. More recently he has been a leader in the application of novel modeling and simulation methods to improve clinical trial designs and drug development. Dr. Lalonde is a graduate of the University of Minnesota (Pharm.D.) and the University of Toronto (B.Sc. Pharmacy).
Micheline Piquette-Miller, PhD
Dr. Piquette-Miller is an Associate Professor and Director of the Division of Pharmaceutical Sciences at the University of Toronto. She received her BSc and PhD in Pharmaceutical Sciences from the University of Alberta and continued her postdoctoral research studies at the Department of Biopharmaceutical and Molecular Pharmacology at the University of California, San Francisco. Dr. Piquette-Miller is the President of the Canadian Society of Clinical Pharmacology and has served on the Board of Directors and Chair of the Pharmacogenetics and Molecular Pharmacology Section for ASCPT. She has been the recipient of numerous awards and honors for her research in the areas of drug transport and multidrug resistance including the 2006 Leon I. Goldberg Young Investigator Award from ASCPT.
Kellie Reynolds, PharmD
Dr. Reynolds is the deputy director of the Division of Clinical Pharmacology 4 in the Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS), Center for Drug Evaluation and Research (CDER), FDA. Dr. Reynolds received her Pharm.D. from the School of Pharmacy at Virginia Commonwealth University and continued her training at the University of North Carolina at Chapel Hill, where she completed a fellowship in Clinical Pharmacokinetics and Drug Development. Her current work involves the application of clinical pharmacology to the development of anti-viral, anti-infective, and transplant drugs. One focus of her work is interpretation of drug interaction data. She helped update the in vitro and in vivo drug interaction guidance for industry. Dr. Reynolds participated in a regulatory research project on in vitro drug metabolism studies and has given many national and international presentations on the clinical interpretation of in vitro drug metabolism data, in vivo drug interaction data, and the design of in vivo drug interaction studies. She has published a number of peer-reviewed articles and book chapters that address drug interactions. Dr. Reynolds' professional and research interests include the pharmacokinetics and pharmacodynamics of drugs used in HIV infected patients, factors affecting drug absorption, drug metabolism, drug interactions, and the application of clinical pharmacology and biopharmaceutics information to the practice of clinical pharmacy.
Brian Smith, PhD
Dr. Smith, a Biostatistics Senior Manager at Amgen Inc., applies statistical methods to analyze early clinical research. Graduating from the University of Kentucky with a PhD in Statistics, Dr. Smith led the group of Clinical Pharmacology and Pharmacokinetic Statisticians at Eli Lilly and Company and eventually the Internal Medicine Program Phase Statistics and Oncology, Cardiovascular, Muskoskeletal Program Phase Statistics groups, assessing data from Phase I and II studies and evaluating statistician and programmer performance. The author of 16 published works and more than 20 oral presentations, Dr. Smith has contributed to the boards, committees, and working groups of professional associations such as the PhRMA Foundation and the American Society for Clinical Pharmacology and Therapeutics.
Alex Sparreboom, PhD
Dr. Sparreboom is an Associate Member of the Department of Pharmaceutical Sciences at St. Jude Children's Research Hospital. He received his BSc, MSc, and PhD in Pharmacy from Utrecht University, and he was previously affiliated with the Daniel den Hoed Cancer Center at Erasmus University and with the National Cancer Institute, NIH. Dr. Sparreboom has published over 250 peer-reviewed articles and book chapters, and he is currently a member of the ASCPT Scientific Program Committee. His research interests focus on the role of solute carriers in anticancer drug disposition and toxicity.
Rachel Tyndale, PhD
Dr. Tyndale is the Canada Research Chair in Pharmacogenetics at the University of Toronto and Director of Pharmacogenetics for the Centre for Addiction and Mental Health. Internationally recognized for breakthrough discoveries in mental health, brain dysfunction, and neurodegenerative disorders, Dr. Tyndale's research will continue to power innovative drug treatments and the personalization of medicine.
Kathleen Uhl, MD
Dr. Uhl is the Director of the Office of Women's Health (OWH) and Assistant Commissioner for Women's Health at the FDA. Dr. Uhl joined the FDA's Center for Drug Evaluation and Research (CDER) as a medical officer in the Office of Clinical Pharmacology and Biopharmaceutics with subsequent positions in both the Office of Postmarketing Drug Risk Assessment and the Pregnancy and Lactation Labeling Team. She has been an active member of numerous working groups in the FDA for the development of Guidance for Industry and Reviewers, and Proposed Rulemaking. She retains dual faculty appointments as associate professor in Family Medicine and Internal Medicine at the Uniformed Services University in Bethesda, MD and is currently a Captain in the Commissioned Corps of the US Public Health Service. Dr. Uhl is also a loyal member of ASCPT, having held previous appointments on the Society's Board of Directors and Strategic Planning Task Force.
John Vincent, MD, PhD
Dr. Vincent is a Director, Worldwide Medical Research and Development, at Pfizer. He received his MD from the University of Nigeria Medical School and continued his education at the University of Glasgow, where he received a PhD. Dr. Vincent is a member of many professional societies such as the New York Academy of Sciences and the American Heart Association where he served on the Council on Hypertension. Dr. Vincent's research interests include receptor pharmacology, autonomic and cardiovascular clinical pharmacology, vascular responsiveness and clinical methodology, cardiac biomarkers and heart failure therapy, ethnic differences in drug responsiveness and Tropical diseases. He serves as a reviewer for several Journals in Clinical Pharmacology and Hypertension. He has also published extensively in the field of Clinical Pharmacology and is the past Chair of the ASCPT Membership Action Committee.
Editorial Board
0009-9236b.pdf
| 
刊名字顺( Alphabetical List of Journals):
返回页首 